



An Evidence-Based Systematic Review of Dream Water® By the Natural Standard Research Collaboration

CLINICAL BOTTOM LINE

Brief Background:

- **Dream Water®:** Dream Water® is a brand of noncaloric functional products that are marketed as dietary supplements to safely promote relaxation and enhance sleep. Introduced in late 2009 after two years of research and development, Dream Water® products contain a propriety formulation of naturally occurring substances that are commonly used for their purported anxiolytic (calming) and sleep-promoting effects: gamma-aminobutyric acid (GABA), melatonin, and 5-hydroxytryptophan (5-HTP).
- **Gamma-aminobutyric acid (GABA):** GABA is a nonprotein amino acid that is the principle inhibitory neurotransmitter in the mammalian central nervous system (3). Most of the immediate synaptic inhibitory effects of GABA are mediated by the GABA(A) class of ligand-gated ion channel receptors; thus, many pharmacological agents (including alcohol and psychoactive drugs) exert anxiolytic, analgesic, anticonvulsant, and sedative effects by modulating GABA(A) receptor activity (4) or by blocking its reuptake (5).
- For many dietary supplements that are used widely for enhancing memory and reducing insomnia, the effects may be achieved through modulating endogenous GABA. These include 5-HTP, hop (*Humulus lupulus*), kava (*Piper methysticum*), lemon balm (*Melissa officinalis*), passion flower (*Passiflora* spp.), skullcap (*Scutellaria* spp.), and valerian (*Valeriana officinalis*) (6).
- A vast body of research has been devoted to the pharmacological effects of endogenous GABA and agents that mimic or potentiate the effects of GABA, including drugs and herbs. In the 1970s and 1980s, synthetic GABA (called aminalton in Russia and gammalon in Japan) was examined as a treatment for various disorders (including autonomic, cardiovascular, and neurological disorders).
- Because endogenous GABA has known relaxant effects (7), supplemental GABA is commonly taken to promote relaxation and as a sleep aid. GABA has also been shown to increase growth hormone (GH) secretion in humans when taken orally; thus, GABA is popularly used as a body building supplement.
- **5-Hydroxytryptophan (5-HTP):** 5-HTP is the precursor of the neurotransmitter serotonin. It is obtained commercially from the seeds of the plant *Griffonia simplicifolia*.
- 5-HTP has been suggested as a treatment for many conditions such as stress, anxiety, panic attacks, and pain. Anxiolytic effects of various dietary supplements, including 5-HTP, have been discussed in a review (6). It has also been suggested that 5-HTP reduces carbohydrate cravings and controls appetite.
- There is some research to support the use of 5-HTP in treating cerebellar ataxia, headache, depression, psychiatric disorders, and fibromyalgia, and as an appetite suppressant or weight-loss agent. There is also some evidence from clinical case studies that 5-HTP may improve sleep.
- **Melatonin:** Endogenous melatonin is an indole neurohormone produced in the brain by the pineal gland, from the amino acid tryptophan (8), and day-night changes in synthesis are regulated by serotonin N-acetyltransferase (9). The synthesis and release of melatonin are stimulated by darkness and suppressed by light, suggesting the involvement of melatonin in circadian rhythm and regulation of diverse body functions. Levels of melatonin in the blood are highest prior to bedtime.
- Melatonin acts on MT(1) and MT(2) melatonin receptors located in the hypothalamic suprachiasmatic nuclei, the site of the body's master circadian clock. Melatonin may reset



Natural Standard

One Davis Square | Somerville, MA 02144 | T: 617.591.3300 | F: 617.758.4274 | www.naturalstandard.com

disturbed circadian rhythms and can promote jet lag recovery and other circadian rhythm sleep disorders, including delayed sleep phase syndrome and work shift sleep disorder (10; 11).

- Administration of exogenous melatonin has been used for a variety of medical conditions, most notably for disorders related to sleep, such as jet lag, delayed sleep phase syndrome (DSPS), and insomnia, for which there exists an ample body of research.
- Many of melatonin's proposed therapeutic or preventive uses are based on its antioxidant activity (12-47).
- New pharmacological agents that block the effects of melatonin are in development, such as BMS-214778 or luzindole, and may have uses in various disorders (48-50).

Expert Opinion and Historic/Folkloric Precedent:

- **Gamma-aminobutyric acid (GABA):** GABA is likely safe to use for short-term, low-dose treatments. The prevailing expert opinion is that the known effects of endogenous GABA in neural tissues are generally not replicated with exogenous GABA supplementation because it does not cross the blood-brain barrier. However, some clinical studies have shown oral GABA supplementation to reduce anxiety (51; 52) and improve sleep (51).
- Because many mood disorders have been associated with low plasma levels of GABA (53), supplementation with exogenous GABA has been suggested for disorders such as anxiety and depression (54).
- As a food additive, GABA (PharmaGABA™ produced by Pharma Foods International Co. Ltd., Kyoto, Japan) has a Generally Recognized as Safe (GRAS) notice on file with the United States Food and Drug Administration (FDA).
- **5-Hydroxytryptophan (5-HTP):** There has been recent interest in the use of 5-HTP as a precursor therapeutic agent to increase serotonin production.
- 5-HTP has orphan drug status for the treatment of post-anoxic myoclonus (Lance-Adams syndrome), a rare complication of successful cardiopulmonary resuscitation.
- Naturopathic practitioners have recommended taking 50-100mg of 5-HTP three times daily for antidepressant effects. It is recommended that 5-HTP be taken at night to reduce daytime drowsiness.
- **Melatonin:** Melatonin is widely recommended for various sleep disorders and for prevention of jet lag. In addition, it is used in conditions believed to be associated with low levels of endogenous melatonin, such as aging, sleep disorders in children, and affective disorders. It has also garnered attention as possibly playing a role in or serving as a treatment for chronic inflammatory diseases (55), cancer (56), and hypertension (57), as well as an antioxidant therapy to counter aging and a variety of metabolic diseases (58).
- A review by Bjorvatn and Pallesen outlined how to estimate circadian rhythm based on a careful patient history and use this estimate to administer melatonin or light to treat delayed sleep phase disorder, advanced sleep phase disorder, free-running, irregular sleep-wake rhythm, jet lag disorder and shift work disorder (59).

ATTRIBUTION/MONOGRAPH CURRENCY

- **Last Updated:** June 3, 2010
- **Authors/Editors:** Tracee Abrams, PharmD (University of Rhode Island); Serguei Axentsev, MD, PhD, DSci (Natural Standard Research Collaboration); Ethan Basch, MD (Memorial Sloan-Kettering Cancer Center); Heather Boon, BScPhm, PhD (University of Toronto); Wendy Chao, PhD (Natural Standard Research Collaboration); Julie Conquer, PhD (RGB Consulting); Michelle Corrado, PharmD (Harvard Vanguard Medical Association); Robert D'Alessandro, MS (Northeastern University); Cynthia Dacey, PharmD (Natural Standard Research Collaboration); Michael Goble, BS, PharmD (Massachusetts College of Pharmacy); Nicole Giese, MS (Natural



Natural Standard

One Davis Square | Somerville, MA 02144 | T: 617.591.3300 | F: 617.758.4274 | www.naturalstandard.com

Standard Research Collaboration); Jill M. Grimes Serrano, PhD (Natural Standard Research Collaboration); Dana Hackman, BS (Northeastern University); Paul Hammerness, MD (Harvard Medical School); Sadaf Hashmi, MD, MPH (Johns Hopkins School of Hygiene and Public Health); Ramon Iovin, PhD (Natural Standard Research Collaboration); Timothy Lavens, PharmD (Wayne State University); Nikos Linardakis, MD (Natural Standard Research Collaboration); Saba Rab, PharmD (Massachusetts College of Pharmacy); Erica Rusie, PharmD (Nova Southeastern University); Toni Schaeffer, PhD, PharmD (Albany College of Pharmacy); Lisa Scully, PharmD (Massachusetts College of Pharmacy); Michael Shaffer, MA (University of Florida); Michael Smith, MRPharmS, ND (Canadian College of Naturopathic Medicine); Shaina Tanguay-Colucci, BS (Natural Standard Research Collaboration); Candy Tsourounis, PharmD (University of California); Catherine Ulbricht, PharmD (Massachusetts General Hospital); Minney Varghese, BS (Natural Standard Research Collaboration); Mamta Vora, PharmD (Northeastern University); Wendy Weissner, BA (Natural Standard Research Collaboration); Regina C. Windsor, MPH (Natural Standard Research Collaboration).

- **Blinded Peer-Review:** Natural Standard Editorial Board.

BIBLIOGRAPHY

1. Korninger, C., Roller, R. E., and Lesch, O. M. Gamma-hydroxybutyric acid in the treatment of alcohol withdrawal syndrome in patients admitted to hospital. *Acta Med Austriaca* 2003;30(3):83-86.
2. Addolorato, G., Caputo, F., Capristo, E., Stefanini, G. F., and Gasbarrini, G. Gamma-hydroxybutyric acid efficacy, potential abuse, and dependence in the treatment of alcohol addiction. *Alcohol* 2000;20(3):217-222.
3. Enna, S. J. GABA. *Advances in Pharmacology*, Volume 54. 2006; San Diego: Academic Press/Elsevier.
4. Belelli, D. and Lambert, J. J. Neurosteroids: endogenous regulators of the GABA(A) receptor. *Nat Rev.Neurosci.* 2005;6(7):565-575.
5. Schwartz, T. L. and Nihalani, N. Tiagabine in anxiety disorders. *Expert.Opin.Pharmacother.* 2006;7(14):1977-1987.
6. Weeks, B. S. Formulations of dietary supplements and herbal extracts for relaxation and anxiolytic action: Relarian. *Med Sci.Monit.* 2009;15(11):RA256-RA262.
7. Meldrum, B. S. GABAergic mechanisms in the pathogenesis and treatment of epilepsy. *Br.J Clin Pharmacol* 1989;27 Suppl 1:3S-11S.
8. Brzezinski, A. Melatonin in humans. *N.Engl.J Med* 1-16-1997;336(3):186-195.
9. Iuvone, P. M., Brown, A. D., Haque, R., Weller, J., Zawilska, J. B., Chaurasia, S. S., Ma, M., and Klein, D. C. Retinal melatonin production: role of proteasomal proteolysis in circadian and photic control of arylalkylamine N-acetyltransferase. *Invest Ophthalmol.Vis.Sci.* 2002;43(2):564-572.



Natural Standard

One Davis Square | Somerville, MA 02144 | T: 617.591.3300 | F: 617.758.4274 | www.naturalstandard.com

10. Srinivasan, V., Spence, D. W., Pandi-Perumal, S. R., Trakht, I., and Cardinali, D. P. Jet lag: therapeutic use of melatonin and possible application of melatonin analogs. *Travel.Med Infect.Dis.* 2008;6(1-2):17-28.
11. Folkard, S., Arendt, J., and Clark, M. Can melatonin improve shift workers' tolerance of the night shift? Some preliminary findings. *Chronobiol.Int* 1993;10(5):315-320.
12. Pei, Z., Fung, P. C., and Cheung, R. T. Melatonin reduces nitric oxide level during ischemia but not blood-brain barrier breakdown during reperfusion in a rat middle cerebral artery occlusion stroke model. *J Pineal Res* 2003;34(2):110-118.
13. Pei, Z. and Cheung, R. T. Melatonin protects SHSY5Y neuronal cells but not cultured astrocytes from ischemia due to oxygen and glucose deprivation. *J Pineal Res* 2003;34(3):194-201.
14. Chen, G., Huo, Y., Tan, D. X., Liang, Z., Zhang, W., and Zhang, Y. Melatonin in Chinese medicinal herbs. *Life Sci.* 5-23-2003;73(1):19-26.
15. Chen, J. C., Ng, C. J., Chiu, T. F., and Chen, H. M. Altered neutrophil apoptosis activity is reversed by melatonin in liver ischemia-reperfusion. *J Pineal Res* 2003;34(4):260-264.
16. Chen, K. B., Lin, A. M., and Chiu, T. H. Oxidative injury to the locus coeruleus of rat brain: neuroprotection by melatonin. *J Pineal Res* 2003;35(2):109-117.
17. Chen, Z., Chua, C. C., Gao, J., Hamdy, R. C., and Chua, B. H. Protective effect of melatonin on myocardial infarction. *Am.J Physiol Heart Circ.Physiol* 2003;284(5):H1618-H1624.
18. Cheung, R. T. The utility of melatonin in reducing cerebral damage resulting from ischemia and reperfusion. *J Pineal Res* 2003;34(3):153-160.
19. Reiter, R. J., Acuna-Castroviejo, D., Tan, D. X., and Burkhardt, S. Free radical-mediated molecular damage. Mechanisms for the protective actions of melatonin in the central nervous system. *Ann N Y Acad Sci* 2001;939:200-215.
20. Reiter RJ, Tan DX, and Manchester LC. Biochemical reactivity of melatonin with reactive oxygen and nitrogen species: a review of the evidence. *Cell Biochem Biophys* 2001;34(2):237-256.
21. Pei, Z., Pang, S. F., and Cheung, R. T. Administration of melatonin after onset of ischemia reduces the volume of cerebral infarction in a rat middle cerebral artery occlusion stroke model. *Stroke* 2003;34(3):770-775.
22. Reiter RJ, Tan DX, Acuña-Castroviejo D, and et al. Melatonin: mechanisms and actions as an antioxidant. *Curr Top Biophys* 2000;24:171-183.
23. Reiter, R. J., Tan, D. X., Manchester, L. C., and El Sawi, M. R. Melatonin reduces oxidant damage and promotes mitochondrial respiration: implications for aging. *Ann.N.Y.Acad.Sci* 2002;959:238-250.
24. Reiter, R. J. and Tan, D. X. Melatonin: an antioxidant in edible plants. *Ann.N.Y.Acad.Sci.* 2002;957:341-344.



Natural Standard

One Davis Square | Somerville, MA 02144 | T: 617.591.3300 | F: 617.758.4274 | www.naturalstandard.com

25. Reiter, R. J., Sainz, R. M., Lopez-Burillo, S., Mayo, J. C., Manchester, L. C., and Tan, D. X. Melatonin ameliorates neurologic damage and neurophysiologic deficits in experimental models of stroke. *Ann.N.Y.Acad.Sci.* 2003;993:35-47.
26. Reiter, R. J. and Tan, D. X. Melatonin: a novel protective agent against oxidative injury of the ischemic/reperfused heart. *Cardiovasc.Res* 4-1-2003;58(1):10-19.
27. Reiter, R. J. Melatonin: clinical relevance. *Best.Pract.Res Clin Endocrinol.Metab* 2003;17(2):273-285.
28. Reiter, R. J. and Tan, D. X. What constitutes a physiological concentration of melatonin? *J Pineal Res* 2003;34(1):79-80.
29. Sahna, E., Parlakpınar, H., Ozturk, F., Cigremis, Y., and Acet, A. The protective effects of physiological and pharmacological concentrations of melatonin on renal ischemia-reperfusion injury in rats. *Urol.Res* 2003;31(3):188-193.
30. Sahna, E., Acet, A., Ozer, M. K., and Olmez, E. Myocardial ischemia-reperfusion in rats: reduction of infarct size by either supplemental physiological or pharmacological doses of melatonin. *J Pineal Res* 2002;33(4):234-238.
31. Sahna, E., Olmez, E., and Acet, A. Effects of physiological and pharmacological concentrations of melatonin on ischemia-reperfusion arrhythmias in rats: can the incidence of sudden cardiac death be reduced? *J Pineal Res* 2002;32(3):194-198.
32. Sener, G., Sehirli, A. O., and Ayanoglu-Dulger, G. Protective effects of melatonin, vitamin E and N-acetylcysteine against acetaminophen toxicity in mice: a comparative study. *J Pineal Res* 2003;35(1):61-68.
33. Sener, G., Tosun, O., Sehirli, A. O., Kacmaz, A., Arbak, S., Ersoy, Y., and Ayanoglu-Dulger, G. Melatonin and N-acetylcysteine have beneficial effects during hepatic ischemia and reperfusion. *Life Sci.* 5-2-2003;72(24):2707-2718.
34. Sener, G., Sehirli, A. O., Paskaloglu, K., Dulger, G. A., and Alican, I. Melatonin treatment protects against ischemia/reperfusion-induced functional and biochemical changes in rat urinary bladder. *J Pineal Res* 2003;34(3):226-230.
35. Celebi, S., Dilsiz, N., Yilmaz, T., and Kukner, A. S. Effects of melatonin, vitamin E and octreotide on lipid peroxidation during ischemia-reperfusion in the guinea pig retina. *Eur.J Ophthalmol.* 2002;12(2):77-83.
36. Li, X. J., Zhang, L. M., Gu, J., Zhang, A. Z., and Sun, F. Y. Melatonin decreases production of hydroxyl radical during cerebral ischemia-reperfusion. *Zhongguo Yao Li Xue.Bao.* 1997;18(5):394-396.
37. Lee, Y. M., Chen, H. R., Hsiao, G., Sheu, J. R., Wang, J. J., and Yen, M. H. Protective effects of melatonin on myocardial ischemia/reperfusion injury in vivo. *J Pineal Res* 2002;33(2):72-80.
38. Zhang, J., Guo, J. D., Xing, S. H., Gu, S. L., and Dai, T. J. [The protective effects of melatonin on global cerebral ischemia-reperfusion injury in gerbils]. *Yao Xue.Xue.Bao.* 2002;37(5):329-333.



Natural Standard

One Davis Square | Somerville, MA 02144 | T: 617.591.3300 | F: 617.758.4274 | www.naturalstandard.com

39. Zhang, Z. and Yu, C. X. [Effect of melatonin on learning and memory impairment induced by aluminum chloride and its mechanism]. Yao Xue.Xue.Bao. 2002;37(9):682-686.
40. Mayo, J. C., Tan, D. X., Sainz, R. M., Natarajan, M., Lopez-Burillo, S., and Reiter, R. J. Protection against oxidative protein damage induced by metal-catalyzed reaction or alkylperoxy radicals: comparative effects of melatonin and other antioxidants. Biochim.Biophys.Acta 3-17-2003;1620(1-3):139-150.
41. Sainz, R. M., Mayo, J. C., Tan, D. X., Lopez-Burillo, S., Natarajan, M., and Reiter, R. J. Antioxidant activity of melatonin in Chinese hamster ovarian cells: changes in cellular proliferation and differentiation. Biochem.Biophys.Res Commun. 3-14-2003;302(3):625-634.
42. Tan, D. X., Hardeland, R., Manchester, L. C., Poeggeler, B., Lopez-Burillo, S., Mayo, J. C., Sainz, R. M., and Reiter, R. J. Mechanistic and comparative studies of melatonin and classic antioxidants in terms of their interactions with the ABTS cation radical. J Pineal Res 2003;34(4):249-259.
43. Pieri C, Moroni M, Marcheselli F, and et al. Melatonin is an efficient antioxidant. Arch Gerontol Geriatr 1995;20:159-165.
44. Gulcin, I., Buyukokuroglu, M. E., Oktay, M., and Kufrevioglu, O. I. On the in vitro antioxidative properties of melatonin. J Pineal Res 2002;33(3):167-171.
45. Gulcin, I., Buyukokuroglu, M. E., and Kufrevioglu, O. I. Metal chelating and hydrogen peroxide scavenging effects of melatonin. J Pineal Res 2003;34(4):278-281.
46. Forrest, C. M., Mackay, G. M., Stoy, N., Stone, T. W., and Darlington, L. G. Inflammatory status and kynurenine metabolism in rheumatoid arthritis treated with melatonin. Br.J Clin Pharmacol 2007;64(4):517-526.
47. Caumo, W., Torres, F., Moreira, N. L., Jr., Auzani, J. A., Monteiro, C. A., Londero, G., Ribeiro, D. F., and Hidalgo, M. P. The clinical impact of preoperative melatonin on postoperative outcomes in patients undergoing abdominal hysterectomy. Anesth.Analg. 2007;105(5):1263-71.
48. Vachharajani, N. N., Yeleswaram, K., and Boulton, D. W. Preclinical pharmacokinetics and metabolism of BMS-214778, a novel melatonin receptor agonist. J Pharm Sci. 2003;92(4):760-772.
49. Zhou, M. O., Jiao, S., Liu, Z., Zhang, Z. H., and Mei, Y. A. Luzindole, a melatonin receptor antagonist, inhibits the transient outward K⁺ current in rat cerebellar granule cells. Brain Res 4-25-2003;970(1-2):169-177.
50. Constantinescu, C. S., Hilliard, B., Ventura, E., and Rostami, A. Luzindole, a melatonin receptor antagonist, suppresses experimental autoimmune encephalomyelitis. Pathobiology 1997;65(4):190-194.
51. Gamma-aminobutyric acid (GABA), Monograph. Altern.Med Rev. 2007;12(3):274-279.
52. Abdou, A. M., Higashiguchi, S., Horie, K., Kim, M., Hatta, H., and Yokogoshi, H. Relaxation and immunity enhancement effects of gamma-aminobutyric acid (GABA) administration in humans. Biofactors 2006;26(3):201-208.



Natural Standard

One Davis Square | Somerville, MA 02144 | T: 617.591.3300 | F: 617.758.4274 | www.naturalstandard.com

53. Petty, F. Plasma concentrations of gamma-aminobutyric acid (GABA) and mood disorders: a blood test for manic depressive disease? *Clin Chem.* 1994;40(2):296-302.
54. Braverman, E. R. and Pfeifer, C. C. *The healing nutrients within: facts, findings, and new research on amino acids.* 2003; North Bergen, NJ: Basic Health Publ.
55. Kalpakcioglu, B. and Senel, K. The role of melatonin in rheumatic diseases. *Infect.Disord.Drug Targets.* 2009;9(4):453-456.
56. Jung-Hynes, B., Reiter, R. J., and Ahmad, N. Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer. *J Pineal Res* 2010;48(1):9-19.
57. Simko, F. and Pechanova, O. Potential roles of melatonin and chronotherapy among the new trends in hypertension treatment. *J Pineal Res* 2009;47(2):127-133.
58. Korkmaz, A., Reiter, R. J., Topal, T., Manchester, L. C., Oter, S., and Tan, D. X. Melatonin: an established antioxidant worthy of use in clinical trials. *Mol.Med* 2009;15(1-2):43-50.
59. Bjorvatn, B. and Pallesen, S. A practical approach to circadian rhythm sleep disorders. *Sleep Med Rev.* 2009;13(1):47-60.